[go: up one dir, main page]

SG11201408494UA - Anti-cd70 antibody drug conjugates - Google Patents

Anti-cd70 antibody drug conjugates

Info

Publication number
SG11201408494UA
SG11201408494UA SG11201408494UA SG11201408494UA SG11201408494UA SG 11201408494U A SG11201408494U A SG 11201408494UA SG 11201408494U A SG11201408494U A SG 11201408494UA SG 11201408494U A SG11201408494U A SG 11201408494UA SG 11201408494U A SG11201408494U A SG 11201408494UA
Authority
SG
Singapore
Prior art keywords
drug conjugates
antibody drug
antibody
conjugates
drug
Prior art date
Application number
SG11201408494UA
Inventor
Richard S Barnett
Nick Knudsen
Ying Sun
Sandra Biroc
Timothy Buss
Tsotne Javahishvili
Damien Bresson
Shailaja Srinagesh
Amha Hewet
Jason K Pinkstaff
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of SG11201408494UA publication Critical patent/SG11201408494UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
SG11201408494UA 2012-06-19 2013-06-19 Anti-cd70 antibody drug conjugates SG11201408494UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661782P 2012-06-19 2012-06-19
PCT/US2013/046669 WO2013192360A1 (en) 2012-06-19 2013-06-19 Anti-cd70 antibody drug conjugates

Publications (1)

Publication Number Publication Date
SG11201408494UA true SG11201408494UA (en) 2015-02-27

Family

ID=48700005

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408494UA SG11201408494UA (en) 2012-06-19 2013-06-19 Anti-cd70 antibody drug conjugates

Country Status (13)

Country Link
US (4) US10208123B2 (en)
EP (3) EP3488870B1 (en)
JP (3) JP6343609B2 (en)
KR (3) KR102190832B1 (en)
CN (2) CN111499684B (en)
AU (1) AU2013277169B2 (en)
CA (1) CA2877124A1 (en)
ES (2) ES2712648T3 (en)
IL (3) IL322344A (en)
MX (3) MX359449B (en)
NZ (2) NZ703581A (en)
SG (1) SG11201408494UA (en)
WO (1) WO2013192360A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN104662000B (en) * 2012-05-15 2018-08-17 索伦托医疗有限公司 Drug conjugates and its coupling method and purposes
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
US10201614B2 (en) 2013-03-15 2019-02-12 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (en) * 2013-04-25 2014-10-31 Pf Medicament DERIVATIVES OF DOLASTATIN 10 AND AURISTATINES
US10836821B2 (en) 2013-10-15 2020-11-17 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
BR112016015105A8 (en) 2013-12-27 2018-04-24 Var2 Pharmaceuticals Aps var2csa-drug conjugates
RU2692563C2 (en) 2014-04-25 2019-06-25 Пьер Фабр Медикамент Conjugate of anti-igf-1r antibody with drug and use thereof for treating cancer
HRP20192254T1 (en) 2014-04-25 2020-03-06 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10450378B2 (en) 2014-09-17 2019-10-22 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3226909A1 (en) * 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
JP6607634B2 (en) * 2015-09-04 2019-11-20 学校法人 岩手医科大学 TAF15 gene and target product as target molecule for suppressing tumor recurrence
TWI618697B (en) 2015-11-03 2018-03-21 財團法人工業技術研究院 Compounds, linker-drugs and ligand-drug conjugates
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
CN114191428B (en) 2016-03-02 2024-09-24 卫材研究发展管理有限公司 Eribulin-based antibody-drug conjugates and methods of use
KR102670432B1 (en) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 Modified relaxin polypeptides containing pharmacokinetic enhancers and uses thereof
PT3630977T (en) 2017-06-02 2024-04-24 Ambrx Inc Methods and compositions for promoting non-natural amino acid-containing protein production
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
CN108404138B (en) * 2018-03-09 2020-04-17 中国药科大学 Conjugate of targeting CD24 monoclonal antibody and diethylamine azonium dialkoxide and application thereof
JP2020019723A (en) * 2018-07-30 2020-02-06 国立大学法人 鹿児島大学 Complex of anti-CD70 antibody and IgG binding peptide
CN109232712B (en) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 Preparation method of intermediate for antibody drug conjugate
IL317123A (en) 2018-08-27 2025-01-01 Regeneron Pharma Use of Raman Spectroscopy in Downstream Purification
BR112021003843A2 (en) 2018-08-28 2021-05-25 Ambrx, Inc. anti-cd3 antibody folate biconjugates and their uses
CN109799352B (en) * 2019-01-29 2022-03-08 北京健坤禾润科技有限公司 Chemiluminescent reagent and application thereof in immunoassay
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CN114685657B (en) * 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 Development and application of a functionally enhanced antibody blocker
WO2023000131A1 (en) 2021-07-19 2023-01-26 烟台迈百瑞国际生物医药股份有限公司 Antibody drug conjugate loaded with double toxins and application thereof
US20240245609A1 (en) * 2021-07-20 2024-07-25 Novocodex Biopharmaceuticals Co., Ltd. Freeze-dried composition containing anti-her2 drug conjugate, freeze-dried preparation and preparation method therefor and use thereof
CN113754769B (en) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 CD 70-targeting antibodies, their preparation and use
CN116023500B (en) * 2021-10-25 2023-07-04 重庆精准生物技术有限公司 Chimeric antigen receptor targeting fully humanized CD70 and application thereof
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
CN115708810A (en) * 2022-11-03 2023-02-24 浙江新码生物医药有限公司 Freeze-dried composition containing anti-CD 70-drug conjugate, freeze-dried preparation, preparation method and application thereof
KR20250134670A (en) 2023-01-16 2025-09-11 암브룩스, 인코포레이티드 anti-CD70 antibody-drug conjugate
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
TW202521564A (en) * 2023-08-14 2025-06-01 美商英特利亞醫療公司 Cd70 car-t compositions and methods for cell-based therapy
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118754934B (en) * 2024-06-05 2025-02-07 浙江新码生物医药有限公司 A toxin derivative for preparing drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
CN118846111B (en) * 2024-06-27 2025-12-26 浙江新码生物医药有限公司 An anti-TROP2 antibody-drug conjugate, its preparation method and uses

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
CA1336076C (en) 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
MXPA03009566A (en) 2001-04-19 2004-12-06 Scripps Research Inst Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs.
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
MXPA05006836A (en) 2002-12-22 2005-08-16 Scripps Research Inst Protein arrays.
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
CA2516455C (en) * 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1812031B1 (en) 2004-11-01 2015-06-24 The Regents of the University of California Compositions and methods for modification of biomolecules
ZA200704925B (en) * 2004-12-22 2009-11-25 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
EP2511299A1 (en) * 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
EA016186B1 (en) 2005-09-26 2012-03-30 Медарекс, Инк. Human monoclonal antibodies to cd70 and use thereof
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
CN101605906A (en) * 2006-12-14 2009-12-16 梅达雷克斯公司 Human antibodies that bind CD70 and uses thereof
KR20090100407A (en) * 2006-12-18 2009-09-23 암브룩스, 인코포레이티드 Compositions containing non-natural amino acids and polypeptides, methods comprising non-natural amino acids and polypeptides, and uses of non-natural amino acids and polypeptides
CA2692021A1 (en) * 2007-06-28 2008-12-31 Capsutech Ltd Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
BR112013030362B1 (en) * 2011-05-27 2022-08-30 Ambrx, Inc COMPOUND DERIVED FROM DOLASTATIN, METHOD TO DERIVATIZE IT AND PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUND
EP2714684B1 (en) * 2011-05-27 2018-09-05 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CN104619349B (en) * 2012-06-07 2018-07-10 Ambrx公司 Prostate Specific Membrane Antigen Antibody Drug Conjugate
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
WO2014013401A1 (en) 2012-07-14 2014-01-23 Indian Oil Corporation Limited Ziegler-natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same
US9796854B1 (en) * 2016-07-07 2017-10-24 Intuitive Surgical Operations, Inc. Method of synthesizing near IR, closed chain sulfo-cyanine dyes

Also Published As

Publication number Publication date
EP2861262A1 (en) 2015-04-22
US20250002595A1 (en) 2025-01-02
AU2013277169A1 (en) 2015-01-29
CN104619351A (en) 2015-05-13
IL322344A (en) 2025-09-01
CN111499684A (en) 2020-08-07
MX359449B (en) 2018-09-28
NZ703581A (en) 2016-09-30
EP3488870A1 (en) 2019-05-29
IL236323A0 (en) 2015-02-26
JP2018168155A (en) 2018-11-01
KR102190832B1 (en) 2020-12-15
JP6343609B2 (en) 2018-06-13
IL278638B1 (en) 2025-09-01
JP2015523359A (en) 2015-08-13
EP2861262B1 (en) 2018-11-28
US12037405B2 (en) 2024-07-16
JP6756774B2 (en) 2020-09-16
US10208123B2 (en) 2019-02-19
AU2013277169B2 (en) 2017-02-02
JP7183215B2 (en) 2022-12-05
EP4406612A8 (en) 2025-03-12
US20190338039A1 (en) 2019-11-07
IL278638A (en) 2020-12-31
WO2013192360A1 (en) 2013-12-27
EP4406612A3 (en) 2024-10-16
EP3488870B1 (en) 2024-03-20
US20150141624A1 (en) 2015-05-21
NZ724593A (en) 2019-05-31
EP4406612A2 (en) 2024-07-31
CA2877124A1 (en) 2013-12-27
KR20150032716A (en) 2015-03-27
CN104619351B (en) 2020-01-21
ES2712648T3 (en) 2019-05-14
KR102490719B1 (en) 2023-01-19
IL236323B (en) 2020-11-30
MX2023010178A (en) 2023-09-07
US20230295320A1 (en) 2023-09-21
CN111499684B (en) 2024-10-22
JP2020143151A (en) 2020-09-10
MX2018011836A (en) 2020-09-14
KR20200140399A (en) 2020-12-15
KR20210148388A (en) 2021-12-07
KR102332435B1 (en) 2021-12-01
ES2984397T3 (en) 2024-10-29
MX2014015878A (en) 2015-08-14
IL278638B2 (en) 2026-01-01
US11459392B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
IL278638B2 (en) Anti-cd70 antibody drug conjugates
CY2023013I2 (en) PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES
ZA201502267B (en) Pyrrolobenzodiazepine-anti-her2 antibody conjugates
PL2906253T3 (en) Pyrrolobenzodiazepine - anti-psma antibody conjugates
LT2906251T (en) Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ZA201505656B (en) Antibody drug conjugates
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
IL235807A0 (en) Immunoconjugates comprising anti-cd79b antibodies
DK2858676T3 (en) PROSTATA-SPECIFIC MEMBRAN ANTIGEN ANTISTOF MEDICINE CONJUGATES
IL235989A0 (en) Immunoconjugates comprising anti-cd79b antibodies
ZA201508487B (en) Antibody drug conjugates
DK2917244T3 (en) APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES